Pricing Log in Create free account
Friday 6 November 2026 Export ELAN’s income statement to Excel — free account

Elanco Animal Health Incorporated

ELAN Healthcare Drug Manufacturers Specialty & Generic

Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.

Revenue
+10.2%
EPS
+450.0%
Free cash flow
+35.6%
Total debt
−6.91%

Quarter to June 2026, against a year earlier

23.74 1.57 −6.20%
Market cap
$11.8B
P/E
0.0×
Fwd P/E
161×
Dividend yield
—
F-score
5/9
Altman Z
1.28
Beneish M
−2.68
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Elanco Animal Health Incorporated (ELAN) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Elanco Animal Health Incorporated (ELAN) trades at a EV/EBITDA of 19.7×. Over the past ten years it has ranged from 0.0× (September 2024) to 98.2× (November 2021); the current reading is higher than 58% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 12.2× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 21.2× 64.15%
FY2024 12.9× —
FY2023 0.0× —
FY2022 13.0× (74.18%)
FY2021 50.5× —
FY2020 0.0× —
FY2019 25.8× 6.22%
FY2018 24.3× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 20.3× (2.19%)
Mar 2026 20.7× (2.11%)
Dec 2025 21.2× 35.95%
Sep 2025 15.6× 21.34%
31 more quarters

Against its own ten years

Low 0.0× High 98.2×
Ten-year median 15.8×
Current reading's percentile 58

EV/EBITDA against peers

Company EV/EBITDA
HIMS Hims & Hers Health, Inc. compare n/m
VTRS Viatris Inc. compare 12.3×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 14.3×
NBIX Neurocrine Biosciences, Inc. compare 16.5×
LNTH Lantheus Holdings, Inc. compare 16.7×
ELAN Elanco Animal Health Incorporated 19.7×
RDY Dr. Reddy's Laboratories Ltd compare 22.9×
ALKS Alkermes plc compare 37.9×
KNSA Kiniksa Pharmaceuticals International, plc compare 48.0×
Drug Manufacturers Specialty & Generic industry median 12.2×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on ELAN